BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36175084)

  • 1. Cluster Analysis of DSC MRI, Dynamic Contrast-Enhanced MRI, and DWI Parameters Associated with Prognosis in Patients with Glioblastoma after Removal of the Contrast-Enhancing Component: A Preliminary Study.
    Chung H; Seo H; Choi SH; Park CK; Kim TM; Park SH; Won JK; Lee JH; Lee ST; Lee JY; Hwang I; Kang KM; Yun TJ
    AJNR Am J Neuroradiol; 2022 Nov; 43(11):1559-1566. PubMed ID: 36175084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value.
    Hwang I; Choi SH; Park CK; Kim TM; Park SH; Won JK; Kim IH; Lee ST; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
    AJNR Am J Neuroradiol; 2020 Jan; 41(1):49-56. PubMed ID: 31806595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Prediction Based on Dynamic Contrast-Enhanced MRI and Dynamic Susceptibility Contrast-Enhanced MRI Parameters from Non-Enhancing, T2-High-Signal-Intensity Lesions in Patients with Glioblastoma.
    Jo SW; Choi SH; Lee EJ; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
    Korean J Radiol; 2021 Aug; 22(8):1369-1378. PubMed ID: 33987994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of Dynamic Contrast-Enhanced MRI-Derived Pharmacokinetic Variables in Glioblastoma Patients: Analysis of Contrast-Enhancing Lesions and Non-Enhancing T2 High-Signal Intensity Lesions.
    Kang Y; Hong EK; Rhim JH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SW; Choi SH
    Korean J Radiol; 2020 Jun; 21(6):707-716. PubMed ID: 32410409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Added Prognostic Value of Preoperative Dynamic Contrast-Enhanced MRI Histogram Analysis in Patients with Glioblastoma: Analysis of Overall and Progression-Free Survival.
    Choi YS; Kim DW; Lee SK; Chang JH; Kang SG; Kim EH; Kim SH; Rim TH; Ahn SS
    AJNR Am J Neuroradiol; 2015 Dec; 36(12):2235-41. PubMed ID: 26338911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
    Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
    Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Predictions for Patients with Glioblastoma after Standard Treatment: Application of Contrast Leakage Information from DSC-MRI within Nonenhancing FLAIR High-Signal-Intensity Lesions.
    Kim SH; Cho KH; Choi SH; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST
    AJNR Am J Neuroradiol; 2019 Dec; 40(12):2052-2058. PubMed ID: 31727756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
    Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ
    Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Choi HJ; Choi SH; You SH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park CK; Park SH
    AJNR Am J Neuroradiol; 2021 May; 42(5):853-860. PubMed ID: 33632732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of survival and progression in glioblastoma patients using temporal perfusion changes during radiochemotherapy.
    Larsson C; Groote I; Vardal J; Kleppestø M; Odland A; Brandal P; Due-Tønnessen P; Holme SS; Hope TR; Meling TR; Fosse E; Emblem KE; Bjørnerud A
    Magn Reson Imaging; 2020 May; 68():106-112. PubMed ID: 32004711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: Comparison of intraindividually matched T1 - and T2 (*) -based bolus techniques.
    Bonekamp D; Deike K; Wiestler B; Wick W; Bendszus M; Radbruch A; Heiland S
    J Magn Reson Imaging; 2015 Jul; 42(1):87-96. PubMed ID: 25244574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Initial Area Under the Curve Derived from Dynamic Contrast-Enhanced MRI Improves Prognosis Prediction in Glioblastoma with Unmethylated
    Choi YS; Ahn SS; Lee HJ; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
    AJNR Am J Neuroradiol; 2017 Aug; 38(8):1528-1535. PubMed ID: 28642265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor.
    Jain R; Poisson LM; Gutman D; Scarpace L; Hwang SN; Holder CA; Wintermark M; Rao A; Colen RR; Kirby J; Freymann J; Jaffe CC; Mikkelsen T; Flanders A
    Radiology; 2014 Aug; 272(2):484-93. PubMed ID: 24646147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
    Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator.
    Kolakshyapati M; Adhikari RB; Karlowee V; Takayasu T; Nosaka R; Amatya VJ; Takeshima Y; Akiyama Y; Sugiyama K; Kurisu K; Yamasaki F
    J Neurosurg; 2018 Mar; 128(3):667-678. PubMed ID: 28362236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging.
    Kim R; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
    Eur Radiol; 2017 Mar; 27(3):1176-1185. PubMed ID: 27357131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced-MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma.
    Lin X; Lee M; Buck O; Woo KM; Zhang Z; Hatzoglou V; Omuro A; Arevalo-Perez J; Thomas AA; Huse J; Peck K; Holodny AI; Young RJ
    AJNR Am J Neuroradiol; 2017 Mar; 38(3):485-491. PubMed ID: 27932505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Texture Feature Ratios from Relative CBV Maps of Perfusion MRI Are Associated with Patient Survival in Glioblastoma.
    Lee J; Jain R; Khalil K; Griffith B; Bosca R; Rao G; Rao A
    AJNR Am J Neuroradiol; 2016 Jan; 37(1):37-43. PubMed ID: 26471746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-parametric and multi-regional histogram analysis of MRI: modality integration reveals imaging phenotypes of glioblastoma.
    Li C; Wang S; Serra A; Torheim T; Yan JL; Boonzaier NR; Huang Y; Matys T; McLean MA; Markowetz F; Price SJ
    Eur Radiol; 2019 Sep; 29(9):4718-4729. PubMed ID: 30707277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of Percentage Signal Recovery and Baseline Signal in DSC-MRI Optimized for Relative CBV Measurement for Differentiating Glioblastoma, Lymphoma, Metastasis, and Meningioma.
    Lee MD; Baird GL; Bell LC; Quarles CC; Boxerman JL
    AJNR Am J Neuroradiol; 2019 Sep; 40(9):1445-1450. PubMed ID: 31371360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.